Per una migliore esperienza, mantieni il tuo browser aggiornato. Controlla qui le ultime versioni.

August 2021

Diadem Announces Publication of Clinical Data Showing Its AlzoSure® Biomarker Test Accurately Predicts Progression to Alzheimer’s Disease Six Years Before Diagnosis

Diadem, a company developing the first blood-based test for the early prediction of progression to Alzheimer’s disease (AD), announced results from a retrospective longitudinal study of its AlzoSure® Predict prognostic biomarker test. The study, A conformational variant of p53 (U-p53AZ) as blood-based biomarker for the prediction of the onset of symptomatic Alzheimer’s disease, is now available as a medRxiv preprint prior to its submission to the Journal of Neuroscience. The results confirm that AlzoSure® Predict accurately identifies individuals with no or only minor cognitive impairments who will progress to fully symptomatic Alzheimer’s disease up to six years before dementia symptoms are evident.
Paul Kinnon
CEO at Diadem

 

These results reflect years of innovative research by Diadem scientific co-founder Professor Daniela Uberti, a leader in investigating the role of this conformational p53 variant in the development of Alzheimer’s disease. The new data reinforce and validate our prior studies showing that AlzoSure® Predict can identify individuals who will progress to Alzheimer’s dementia years before symptoms are evident, and it does so more accurately than established diagnostic tools such as PET imaging of amyloid  load. We aim to complete additional validation studies in the coming months and are targeting a global launch in collaboration with strategic partners next year.

 

Read the complete study
act

News

Scopri la sezione News per restare sempre aggiornato su ciò che riguarda gli zoner e sui temi pià rilevanti legati all'innovazione e alle Scienze della Vita.
tutte le news